Steatohepatitis/Metabolic Liver Disease
Article first published online: 14 OCT 2012
Copyright © 2012 American Association for the Study of Liver Diseases
Volume 56, Issue 6, pages 2221–2230, December 2012
How to Cite
Reddy, S. K., Marsh, J. W., Varley, P. R., Mock, B. K., Chopra, K. B., Geller, D. A. and Tsung, A. (2012), Underlying steatohepatitis, but not simple hepatic steatosis, increases morbidity after liver resection: A case-control study. Hepatology, 56: 2221–2230. doi: 10.1002/hep.25935
Potential conflict of interest: Nothing to report.
Abbreviations: AASLD, American Association for the Study of Liver Diseases; ALB, albumin; ASA, American Society of Anesthesiologists; BMI, body mass index; CI, 95% confidence interval; CLD, chronic liver disease; CRCLM, colorectal cancer liver metastases; DM, diabetes mellitus; EBL, estimated blood loss; FLD, fatty liver disease; HCC, hepatocellular carcinoma; HPF, high power field; MetS, metabolic syndrome; NAFLD, nonalcoholic fatty liver disease; NAS, NAFLD activity score; OR, odds ratio; PHI, postoperative hepatic insufficiency; RBC, red blood cell; SH, steatohepatitis; TBIL, total bilirubin.
- Issue published online: 4 DEC 2012
- Article first published online: 14 OCT 2012
- Accepted manuscript online: 5 JUL 2012 04:52PM EST
- Manuscript Accepted: 17 JUN 2012
- Manuscript Received: 24 MAR 2012
Despite the high prevalence of fatty liver disease, the safety of liver resection in settings of steatohepatitis (SH) or hepatic steatosis is poorly understood. The aim of this study was to determine whether underlying SH or simple hepatic steatosis increases morbidity after liver resection. We compared patients undergoing liver resection with underlying SH or greater than 33% simple hepatic steatosis to controls selected for similar demographics, diagnoses, comorbidities, preoperative chemotherapy treatments, and extent of partial hepatectomy. Primary endpoints included postoperative overall and hepatic-related morbidity. One hundred and two patients with SH and 72 with greater than 33% simple hepatic steatosis who underwent liver resection from 2000 to 2011 were compared to corresponding controls. There were no differences in extent or approach of liver resection, malignant indications, preoperative chemotherapy treatment, elements of metabolic syndrome, alcohol use history, American Society of Anesthesiologists score, age, or gender between patients with SH or simple steatosis and corresponding controls. Ninety-day postoperative overall morbidity (56.9% versus 37.3%; P = 0.008), any hepatic-related morbidity (28.4% versus 15.7%; P = 0.043), surgical hepatic complications (19.6% versus 8.8%; P = 0.046), and hepatic decompensation (16.7% versus 6.9%; P = 0.049) were greater among SH patients, compared to corresponding controls. In contrast, there were no differences in postoperative overall morbidity (34.7% versus 44.4%; P = 0.310), any hepatic-related morbidity (19.4% versus 19.4%; P = 1.000), surgical hepatic complications (13.9% versus 9.7%; P = 0.606), or hepatic decompensation (8.3% versus 9.7%; P = 0.778) between simple hepatic steatosis patients and corresponding controls. Using multivariable logistic regression, SH was independently associated with postoperative overall (odds ratio [OR], 2.316; 95% confidence interval [95% CI]: 1.267-4.241; P = 0.007) and any hepatic-related (OR, 2.722; 95% CI: 1.201-6.168; P = 0.016) morbidity. Conclusion: Underlying SH, but not simple hepatic steatosis, increases overall and hepatic-related morbidity after liver resection. (HEPATOLOGY 2012)